Tesamorelin and ipamorelin blend: what is in it and does it work?

What is in the tesamorelin and ipamorelin blend?

Tesamorelin and ipamorelin contains Tesamorelin and Ipamorelin. Products sold under this name combine the two peptides in one vial or as a two-vial kit, in amounts and ratios that vary by seller. The tesamorelin in these products is not the FDA approved Egrifta product and is not made to its standard. PeptideAgent does not name or link sellers.

Also searched as: Tesamorelin ipamorelin blend; Tesamorelin/ipamorelin; Tesamorelin and ipamorelin.

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in the tesamorelin and ipamorelin blend?

The idea is the same as other GHRH and ghrelin mimetic pairings: stimulate growth hormone through both of its release pathways at once. A 1990 study in 18 healthy men found that GHRH and a synthetic ghrelin receptor hexapeptide given together released more growth hormone than either alone.

Tesamorelin brings the strongest evidence of any GHRH analog. In two phase 3 trials with 806 adults with HIV and excess abdominal fat, daily tesamorelin reduced visceral fat by about 15 percent relative to placebo over 26 weeks, and a later NIH funded trial found reduced liver fat. Sellers borrow that record for the blend, but it was earned by tesamorelin alone, in a specific population. [1] [3] [5]

Has the tesamorelin and ipamorelin blend been studied?

No published study has tested tesamorelin with ipamorelin in humans or animals.

The tesamorelin trials enrolled adults with HIV associated lipodystrophy and measured visceral fat by imaging; visceral fat returned toward baseline after treatment stopped. They did not test people without HIV, muscle growth, or combinations with other peptides.

One small human pharmacology study showed a single IV infusion of ipamorelin releases growth hormone in healthy men; its only randomized trial (postoperative ileus) was negative; no human trial measured body composition or muscle. Adding it to tesamorelin has no measured upside and adds an unapproved ingredient. [3] [4] [12]

What each ingredient has shown alone

• Tesamorelin (human RCT evidence). FDA approved lab-made growth hormone releasing hormone (Egrifta, 2010) that cuts deep belly fat about 15% in HIV lipodystrophy and cut liver fat in a trial.
• Ipamorelin (animal-only evidence). Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; raised GH in animals and one small study in men; its only randomized trial failed.

Tesamorelin and ipamorelin results and before and after claims

Measured tesamorelin before and after results come from trials: visceral fat inside the abdomen fell, fat under the skin of the abdomen did not change, and patients rated their belly appearance as improved. A 12 month trial in people with HIV and fatty liver found a lower liver fat fraction. These are real, modest, population-specific results.

No study shows what the blend does. Photos of people using it cannot separate tesamorelin from ipamorelin, diet, training, and other drugs. The tesamorelin trials were not designed to show muscle growth, and none measured it as an outcome.

A 2026 review of growth hormone axis peptides used outside medical care describes how stacking in unregulated supply leaves claimed body recomposition benefits uncertain. [3] [5] [6]

What are the side effects of the tesamorelin and ipamorelin blend?

Tesamorelin's label lists joint pain, injection site reactions, swelling, muscle pain, tingling or numbness, nausea, and rash, and warns about glucose intolerance, raised IGF-1, hypersensitivity, and fluid retention. It is contraindicated in pregnancy, in active malignancy, and in people whose pituitary axis has been disrupted.

Ipamorelin adds an ingredient with no human safety data at the amounts sold, and FDA cited immunogenicity risk from impurities when it placed ipamorelin in Category 2. Stimulating growth hormone by two routes could add up glucose, fluid, and IGF-1 effects; this has not been studied.

A blend made outside the approved product is not manufactured or tested to the approved product's standard, so its tesamorelin content is also unverified. [6] [7] [8]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Is the tesamorelin and ipamorelin blend legal?

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For the tesamorelin and ipamorelin blend that is Ipamorelin: no lawful path. At least one ingredient cannot be lawfully compounded or prescribed, so no licensed pharmacy can lawfully make the mix.

• Tesamorelin regulatory timeline (FDA approved)
• Ipamorelin regulatory timeline (Removed from Category 2 (Apr 2026))

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [10]

WADA status

Tesamorelin and Ipamorelin are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does the tesamorelin and ipamorelin blend cost, and what can a provider lawfully offer?

Tesamorelin is the only peptide in this blend with a lawful path. Egrifta WR is FDA approved and available by prescription. Egrifta WR (a biologic under BLA 022505) is the only lawful product, and biologics fall outside 503A, so tesamorelin cannot be compounded. Use for fat loss in people without HIV is off-label.

Ipamorelin has no lawful path: its compounding nominations were withdrawn, it is not on the 503A bulks list, and it is not a component of an approved drug. A compounded vial that contains ipamorelin cannot be lawfully made, so the blend has no lawful price.

What a prescriber can lawfully offer is tesamorelin by itself, as the approved product Egrifta WR. The tesamorelin cost page lists published prices by channel. [7] [8] [9] [10] [13]

• Tesamorelin cost by channel
• Ipamorelin cost by channel
• Rules by state
• Verified provider directory

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make the tesamorelin and ipamorelin blend lawful. Ipamorelin is not FDA approved and not on the 503A bulks list, so no pharmacy has a lawful basis to compound the mix. [8] [10]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [9] [14] [15] [16]

What changes for you

• No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [9]
• Identity, purity, sterility, and dose accuracy can vary from batch to batch. [8]
• Insurance rarely covers it, so you usually pay cash.
• For tested athletes, the tesamorelin and ipamorelin blend contains at least one ingredient that is prohibited at all times on the WADA list. [11]

What to check

These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:

• A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [9]
• A real evaluation by a licensed prescriber, not just an online form.
• A certificate of analysis for the specific batch.

The approved option is Egrifta WR, by prescription. See Egrifta WR cost by channel.

Compare the ingredients

• Tesamorelin vs ipamorelin
• CJC-1295 vs ipamorelin
• Ipamorelin vs GHRP-6
• Ipamorelin vs MK-677 (ibutamoren)
• Sermorelin vs ipamorelin

Blends that share an ingredient

• CJC-1295 and ipamorelin: CJC-1295 and ipamorelin pair a GHRH analog with a ghrelin mimetic to raise growth hormone. The pair is untested, and neither peptide has a lawful path.
• Sermorelin and ipamorelin: Sermorelin and ipamorelin pair a formerly approved GHRH fragment with a ghrelin mimetic. The pair is untested, and ipamorelin has no lawful path.

Frequently asked questions

From the blog

• Does tesamorelin build muscle? What the trials show

  Tesamorelin raised lean body mass about 1.2 kg in HIV trials and slightly increased trunk muscle area, but no trial tested strength or muscle growth, and it is prohibited in sport.

• Peptide stacks: what each common component has shown alone

  No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols.

• Tesamorelin before and after: what the trials measured

  Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data.

• Tesamorelin prescription: who qualifies and how to get one

  How to get tesamorelin legally: who qualifies for Egrifta WR on label, how off-label prescribing works, why compounded tesamorelin is not lawful, what a visit should check, and cost.

• Tesamorelin vs sermorelin vs ipamorelin: evidence and legality

  Tesamorelin, sermorelin, and ipamorelin compared in one table: mechanism, FDA approval, compounding status, human evidence, and WADA status, with links to each pairwise comparison.

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.